An open-label, single-arm, phase II safety and tolerability study of catumaxomab (anti-EpCAM x anti-CD3) in women with advanced epithelial ovarian cancer after a complete response to chemotherapy

Trial Profile

An open-label, single-arm, phase II safety and tolerability study of catumaxomab (anti-EpCAM x anti-CD3) in women with advanced epithelial ovarian cancer after a complete response to chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2013

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2012 Actual patient number changed from 43 to 47 as reported by ClinicalTrials.gov.
    • 24 Jun 2011 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top